vs
Copart（CPRT）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
Copart的季度营收约是百利高的1.0倍（$1.2B vs $1.1B），Copart净利率更高（35.0% vs -127.8%，领先162.8%），Copart同比增速更快（0.7% vs -2.5%），Copart自由现金流更多（$427.2M vs $148.6M），过去两年Copart的营收复合增速更高（6.4% vs 1.3%）
Copart是一家跨国在线车辆拍卖及再营销服务提供商，服务保险、租车、车队、金融公司等各类汽车经销商，业务覆盖美国、加拿大、英国、德国等11个国家。总部位于美国得克萨斯州达拉斯，拥有200多处实体网点，运营总面积超1万英亩的车辆存放场地。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
CPRT vs PRGO — 直观对比
营收规模更大
CPRT
是对方的1.0倍
$1.1B
营收增速更快
CPRT
高出3.2%
-2.5%
净利率更高
CPRT
高出162.8%
-127.8%
自由现金流更多
CPRT
多$278.6M
$148.6M
两年增速更快
CPRT
近两年复合增速
1.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.1B |
| 净利润 | $403.7M | $-1.4B |
| 毛利率 | — | 32.6% |
| 营业利润率 | 37.3% | -116.0% |
| 净利率 | 35.0% | -127.8% |
| 营收同比 | 0.7% | -2.5% |
| 净利润同比 | 11.5% | -3093.9% |
| 每股收益（稀释后） | $0.41 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRTPRGO
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $1.2B | $1.0B | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.1B | $1.1B | ||
| Q1 24 | $1.0B | $1.1B |
净利润CPRTPRGO
| Q4 25 | $403.7M | $-1.4B | ||
| Q3 25 | $396.4M | $7.5M | ||
| Q2 25 | $406.6M | $-8.4M | ||
| Q1 25 | $387.4M | $-6.4M | ||
| Q4 24 | $362.1M | $-44.4M | ||
| Q3 24 | $322.6M | $-21.0M | ||
| Q2 24 | $382.3M | $-108.4M | ||
| Q1 24 | $325.6M | $2.0M |
毛利率CPRTPRGO
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
营业利润率CPRTPRGO
| Q4 25 | 37.3% | -116.0% | ||
| Q3 25 | 36.7% | 7.0% | ||
| Q2 25 | 37.3% | 4.3% | ||
| Q1 25 | 36.6% | 4.5% | ||
| Q4 24 | 35.4% | 10.0% | ||
| Q3 24 | 33.6% | 7.4% | ||
| Q2 24 | 38.8% | -2.5% | ||
| Q1 24 | 37.2% | -5.1% |
净利率CPRTPRGO
| Q4 25 | 35.0% | -127.8% | ||
| Q3 25 | 35.2% | 0.7% | ||
| Q2 25 | 33.6% | -0.8% | ||
| Q1 25 | 33.3% | -0.6% | ||
| Q4 24 | 31.6% | -3.9% | ||
| Q3 24 | 30.2% | -1.9% | ||
| Q2 24 | 33.9% | -10.2% | ||
| Q1 24 | 31.9% | 0.2% |
每股收益（稀释后）CPRTPRGO
| Q4 25 | $0.41 | $-10.23 | ||
| Q3 25 | $0.40 | $0.05 | ||
| Q2 25 | $0.42 | $-0.06 | ||
| Q1 25 | $0.40 | $-0.05 | ||
| Q4 24 | $0.37 | $-0.32 | ||
| Q3 24 | $0.34 | $-0.15 | ||
| Q2 24 | $0.39 | $-0.79 | ||
| Q1 24 | $0.33 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.6B | $2.9B |
| 总资产 | $10.6B | $8.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRTPRGO
| Q4 25 | — | — | ||
| Q3 25 | — | $432.1M | ||
| Q2 25 | — | $454.2M | ||
| Q1 25 | — | $409.9M | ||
| Q4 24 | — | $558.8M | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $542.8M | ||
| Q1 24 | — | $658.5M |
总债务CPRTPRGO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $427.0K | — | ||
| Q1 24 | $453.0K | — |
股东权益CPRTPRGO
| Q4 25 | $9.6B | $2.9B | ||
| Q3 25 | $9.2B | $4.4B | ||
| Q2 25 | $8.8B | $4.5B | ||
| Q1 25 | $8.3B | $4.4B | ||
| Q4 24 | $7.9B | $4.3B | ||
| Q3 24 | $7.5B | $4.6B | ||
| Q2 24 | $7.2B | $4.5B | ||
| Q1 24 | $6.8B | $4.7B |
总资产CPRTPRGO
| Q4 25 | $10.6B | $8.5B | ||
| Q3 25 | $10.1B | $10.1B | ||
| Q2 25 | $9.7B | $10.1B | ||
| Q1 25 | $9.2B | $9.8B | ||
| Q4 24 | $8.9B | $9.6B | ||
| Q3 24 | $8.4B | $11.2B | ||
| Q2 24 | $8.0B | $10.4B | ||
| Q1 24 | $7.6B | $10.6B |
负债/权益比CPRTPRGO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $535.3M | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $427.2M | $148.6M |
| 自由现金流率自由现金流/营收 | 37.0% | 13.4% |
| 资本支出强度资本支出/营收 | 9.4% | 2.4% |
| 现金转化率经营现金流/净利润 | 1.33× | — |
| 过去12个月自由现金流最近4个季度 | $1.4B | $145.1M |
8季度趋势，按日历期对齐
经营现金流CPRTPRGO
| Q4 25 | $535.3M | $175.4M | ||
| Q3 25 | $438.5M | $51.7M | ||
| Q2 25 | $700.9M | $75.9M | ||
| Q1 25 | $178.1M | $-64.5M | ||
| Q4 24 | $482.3M | $312.6M | ||
| Q3 24 | $439.2M | $42.2M | ||
| Q2 24 | $496.3M | $9.5M | ||
| Q1 24 | $161.8M | $-1.4M |
自由现金流CPRTPRGO
| Q4 25 | $427.2M | $148.6M | ||
| Q3 25 | $350.8M | $29.8M | ||
| Q2 25 | $572.9M | $56.7M | ||
| Q1 25 | $61.5M | $-90.0M | ||
| Q4 24 | $245.5M | $274.9M | ||
| Q3 24 | $301.3M | $15.1M | ||
| Q2 24 | $408.5M | $-18.9M | ||
| Q1 24 | $38.8M | $-26.5M |
自由现金流率CPRTPRGO
| Q4 25 | 37.0% | 13.4% | ||
| Q3 25 | 31.2% | 2.9% | ||
| Q2 25 | 47.3% | 5.4% | ||
| Q1 25 | 5.3% | -8.6% | ||
| Q4 24 | 21.4% | 24.2% | ||
| Q3 24 | 28.2% | 1.4% | ||
| Q2 24 | 36.2% | -1.8% | ||
| Q1 24 | 3.8% | -2.4% |
资本支出强度CPRTPRGO
| Q4 25 | 9.4% | 2.4% | ||
| Q3 25 | 7.8% | 2.1% | ||
| Q2 25 | 10.6% | 1.8% | ||
| Q1 25 | 10.0% | 2.4% | ||
| Q4 24 | 20.6% | 3.3% | ||
| Q3 24 | 12.9% | 2.5% | ||
| Q2 24 | 7.8% | 2.7% | ||
| Q1 24 | 12.1% | 2.3% |
现金转化率CPRTPRGO
| Q4 25 | 1.33× | — | ||
| Q3 25 | 1.11× | 6.89× | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | 1.36× | — | ||
| Q2 24 | 1.30× | — | ||
| Q1 24 | 0.50× | -0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRT
| Services | $952.1M | 82% |
| Other | $203.0M | 18% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
